ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Conversion therapy using transarterial chemoembolization plus tislelizumab for unresectable hepatocellular carcinoma: effects on tumor necrosis and anti-tumor immune response.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe analyzed the clinical efficacy and safety of conversion therapy for unresectable hepatocellular carcinoma (uHCC) using transarterial chemoembolization (TACE) plus tislelizumab and characterized its effects on the tumor and immune landscape.
methodsFifty-seven patients with uHCC undergoing TACE plus tislelizumab from March 2020 to October 2024 were potentially eligible, and thirty-two patients finally enrolled. The efficacy endpoints included successful conversion rate, objective response rate (ORR), overall survival (OS), and progression-free survival (PFS). Tumor response was assessed using modified Response Evaluation Criteria in Solid Tumors (mRECIST). Treatment-related adverse events (TRAEs) were recorded according to CTCAE v5.0. Hematoxylin and eosin (HE) staining was used to evaluate tumor necrosis and lymphocyte infiltration. Immunohistochemistry (IHC) was performed to differentiate tumor immune infiltrates via a set of markers.
resultsThe best overall responses were 9.4% CR, 46.9% PR, 37.5% SD, and 6.3% PD, the ORR was 56.3%. Better ORR was shown in patients with AFP ≥ 400 ng/mL or tumor number < 3. The median PFS and OS was 13.9 (95% CI 2.6-25.2) and 29.2 (95% CI 13.7-44.7) months, respectively. Thirty-two patients (100%) experienced TRAEs of any grade, eight patients (25%) experienced grade 3/4 TRAEs. Fifteen patients (46.9%) with uHCC successfully converted. Notably, HE staining revealed extensive tumor necrosis and massive infiltration of lymphocytes in HCC and at the tumor-non-tumor interface in converted specimens. Further characterization by IHC revealed increased infiltration of CD8 + T and Th1 cells in the tumor of converted patients.
conclusionTACE plus tislelizumab may be a potent and safe conversion regimen for uHCC due to its ability to generate profound tumor necrosis and anti-tumor immune response.
Indexed as
Identifiers
41493694What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.